However, clinical trials in osteosarcoma have shown that single‐target therapy, such as inhibiting VEGFs (with bevacizumab), KIT and PDGFRα (with imatinib), or IGF‐1R (with cixutumumab or R1507) has limited efficacy. Here, PDGFRA is linked to osteosarcoma.